Eosinophilic Esophagitis Pipeline Review and Market Analysis, H2 2015 adds Eosinophilic Esophagitis - Pipeline Review, H2 2015 to its store. This report provides an overview of the Eosinophilic Esophagitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Companies mentioned in this report are Allergan Plc, DBV Technologies S.A., Dr. Falk Pharma GmbH, Novartis AG, Receptos, Inc., Regeneron Pharmaceuticals, Inc., Shire Plc.

Get a copy of this report at . (This is a premium report price at US$2000 for a single user PDF license)

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages